Successful long-term use of pioglitazone in Berardinelli–Seip lipodystrophy-associated diabetes

• Main Authors: Carolina Chaves, Mariana Chaves, João Anselmo, Rui César
• Format: Article
• Language: English
• Published: Bioscientifica 2021-04-01
• Series: Endocrinology, Diabetes & Metabolism Case Reports
• Online Access: https://edm.bioscientifica.com/view/journals/edm/2021/1/EDM20-0183.xml

Berardinelli–Seip congenital lipodystrophy (BSCL) is a rare autosomal recessive disease, characterized by the absence of subcutaneous adipose tissue, leptin deficiency and severe metabolic complications, such as insulin resistance, diabetes mellitus, and dyslipidemia. The most common mutation occurs in BCSL2 which encodes seipin, a protein involved in adipogenesis. We report a patient with BSCL who was diagnosed with diabetes at 11 years old. He was started on metformin 1000 mg twice daily, which lowered glycated hemoglobin (HbA1c) to less than 7%. Four months later, HbA1c raised above 7.5%, indicating secondary failure to metformin. Therefore, we added the peroxisome proliferator-activated receptor-gamma (PPARG) agonist, pioglitazone. Since then and for the last 5 years his HbA1c has been within the normal range. These findings indicate that pioglitazone should be considered as a valid alternative in the treatment of diabetes in BSCL patients. To the best of our knowledge, this is the first specific report of successful long-term treatment with pioglitazone in a patient with BSCL.